Literature DB >> 20561658

Surviving lethal septic shock without fluid resuscitation in a rodent model.

Yongqing Li1, Baoling Liu, Eugene Y Fukudome, Ashley R Kochanek, Robert A Finkelstein, Wei Chong, Guang Jin, Jennifer Lu, Marc A deMoya, George C Velmahos, Hasan B Alam.   

Abstract

BACKGROUND: We have recently demonstrated that treatment with suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, before a lethal dose of lipopolysaccharide (LPS) improves survival in mice. The purpose of the present study was to determine whether SAHA treatment would attenuate LPS-induced shock and improve survival when given postinsult in a rodent model.
METHODS: C57BL/6J mice were intraperitoneally (IP) injected with LPS (30 mg/kg), and 2 hours later randomized into 2 groups: (1) vehicle animals (n = 10) received dimethyl sulfoxide (DMSO) solution only; and (2) SAHA animals (n = 10) were given SAHA (50 mg/kg, IP) in DMSO solution. Survival was monitored over the next 7 days. In a second study, LPS-injected mice were treated with either DMSO or SAHA as described, and normal (sham) animals served as controls. Lungs were harvested at 4, 6, and 8 hours after LPS injection for analysis of gene expression. In addition, RAW264.7 mouse macrophages were cultured to assess the effects of SAHA post-treatment on LPS-induced inflammation using enzyme-linked immunosorbent assay.
RESULTS: All LPS-injected mice that received the vehicle agent alone died within 24 hours, whereas the SAHA-treated animals displayed a significant improvement in 1 week survival (80% vs 0%; P < .001). LPS insult significantly enhanced gene expression of MyD88, tumor necrosis factor (TNF)-alpha and interleukin (IL)-6, and was associated with an increased protein secretion of TNF-alpha and IL-6 into the cell culture medium. In contrast, SAHA treatment significantly attenuated all of these LPS-related alterations.
CONCLUSION: We report for the first time that administration of SAHA (50 mg/kg IP) after a lethal dose of LPS significantly improves long-term survival, and attenuates expression of the proinflammatory mediators TNF-alpha and IL-6. Furthermore, our data suggest that the anti-inflammatory effects of SAHA may be due to downregulation of the MyD88-dependent pathway, and decreased expression of associated proinflammatory genes. Copyright 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20561658      PMCID: PMC4894305          DOI: 10.1016/j.surg.2010.05.003

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  27 in total

1.  The etiology of sepsis: turned inside out.

Authors:  Gregory J Brunn; Jeffrey L Platt
Journal:  Trends Mol Med       Date:  2005-11-18       Impact factor: 11.951

2.  Acetylation of Stat1 modulates NF-kappaB activity.

Authors:  Oliver H Krämer; Daniela Baus; Shirley K Knauer; Stefan Stein; Elke Jäger; Roland H Stauber; Manuel Grez; Edith Pfitzner; Thorsten Heinzel
Journal:  Genes Dev       Date:  2006-02-15       Impact factor: 11.361

Review 3.  HDACi--targets beyond chromatin.

Authors:  Marc Buchwald; Oliver H Krämer; Thorsten Heinzel
Journal:  Cancer Lett       Date:  2009-04-01       Impact factor: 8.679

4.  Valproic acid prevents hemorrhage-associated lethality and affects the acetylation pattern of cardiac histones.

Authors:  Earl Gonzales; Huazhen Chen; Richard Munuve; Tina Mehrani; Joy Britten-Webb; Amal Nadel; Hasan B Alam; David Wherry; David Burris; Elena Koustova
Journal:  Shock       Date:  2006-04       Impact factor: 3.454

5.  Histone hyperacetylation is associated with amelioration of experimental colitis in mice.

Authors:  Rainer Glauben; Arvind Batra; Inka Fedke; Martin Zeitz; Hans A Lehr; Flavio Leoni; Paolo Mascagni; Giamila Fantuzzi; Charles A Dinarello; Britta Siegmund
Journal:  J Immunol       Date:  2006-04-15       Impact factor: 5.422

6.  Progressive dysregulation of transcription factors NF-kappa B and STAT1 in prostate cancer cells causes proangiogenic production of CXC chemokines.

Authors:  Hui Shen; Alex B Lentsch
Journal:  Am J Physiol Cell Physiol       Date:  2003-12-03       Impact factor: 4.249

Review 7.  Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.

Authors:  Aleksey G Kazantsev; Leslie M Thompson
Journal:  Nat Rev Drug Discov       Date:  2008-10       Impact factor: 84.694

8.  p53 Attenuates lipopolysaccharide-induced NF-kappaB activation and acute lung injury.

Authors:  Gang Liu; Young-Jun Park; Yuko Tsuruta; Emmanuel Lorne; Edward Abraham
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

Review 9.  LPS/TLR4 signal transduction pathway.

Authors:  Yong-Chen Lu; Wen-Chen Yeh; Pamela S Ohashi
Journal:  Cytokine       Date:  2008-03-04       Impact factor: 3.861

10.  Aryl hydrocarbon receptor in combination with Stat1 regulates LPS-induced inflammatory responses.

Authors:  Akihiro Kimura; Tetsuji Naka; Taisuke Nakahama; Ichino Chinen; Kazuya Masuda; Keiko Nohara; Yoshiaki Fujii-Kuriyama; Tadamitsu Kishimoto
Journal:  J Exp Med       Date:  2009-08-24       Impact factor: 14.307

View more
  28 in total

1.  Creating a pro-survival and anti-inflammatory phenotype by modulation of acetylation in models of hemorrhagic and septic shock.

Authors:  Yongqing Li; Hasan B Alam
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

2.  Compound 9a, a novel synthetic histone deacetylase inhibitor, protects against septic injury in mice by suppressing MAPK signalling.

Authors:  So-Jin Kim; Ki Seon Baek; Hyun-Ju Park; Young Hoon Jung; Sun-Mee Lee
Journal:  Br J Pharmacol       Date:  2016-02-22       Impact factor: 8.739

3.  Novel pharmacologic treatment attenuates septic shock and improves long-term survival.

Authors:  Ting Zhao; Yongqing Li; Baoling Liu; Zhengcai Liu; Wei Chong; Xiuzhen Duan; Danielle K Deperalta; George C Velmahos; Hasan B Alam
Journal:  Surgery       Date:  2013-08       Impact factor: 3.982

4.  Histone deacetylase inhibitor treatment attenuates MAP kinase pathway activation and pulmonary inflammation following hemorrhagic shock in a rodent model.

Authors:  Ashley R Kochanek; Eugene Y Fukudome; Yongqing Li; Eleanor J Smith; Baoling Liu; George C Velmahos; Marc deMoya; David King; Hasan B Alam
Journal:  J Surg Res       Date:  2011-07-05       Impact factor: 2.192

5.  Histone deacetylase inhibitor treatment attenuates coagulation imbalance in a lethal murine model of sepsis.

Authors:  Ting Zhao; Yongqing Li; Baoling Liu; Erxi Wu; Martin Sillesen; George C Velmahos; Ihab Halaweish; Hasan B Alam
Journal:  Surgery       Date:  2014-06-21       Impact factor: 3.982

Review 6.  Creating a "Prosurvival Phenotype" Through Histone Deacetylase Inhibition: Past, Present, and Future.

Authors:  Ihab Halaweish; Vahagn Nikolian; Patrick Georgoff; Yongqing Li; Hasan B Alam
Journal:  Shock       Date:  2015-08       Impact factor: 3.454

7.  Creating a "pro-survival" phenotype through epigenetic modulation.

Authors:  Yongqing Li; Baoling Liu; Xuesong Gu; Ashley R Kochanek; Eugene Y Fukudome; Zhengcai Liu; Ting Zhao; Wei Chong; Yili Zhao; Dainan Zhang; Towia A Libermann; Hasan B Alam
Journal:  Surgery       Date:  2012-09       Impact factor: 3.982

8.  Citrullinated histone H3: a novel target for the treatment of sepsis.

Authors:  Yongqing Li; Zhengcai Liu; Baoling Liu; Ting Zhao; Wei Chong; Yanming Wang; Hasan B Alam
Journal:  Surgery       Date:  2014-06-21       Impact factor: 3.982

Review 9.  Histone Deacetylase Inhibitors: A Novel Strategy in Trauma and Sepsis.

Authors:  Aaron M Williams; Isabel S Dennahy; Umar F Bhatti; Ben E Biesterveld; Nathan J Graham; Yongqing Li; Hasan B Alam
Journal:  Shock       Date:  2019-09       Impact factor: 3.454

10.  The Effects of Molecular Hydrogen and Suberoylanilide Hydroxamic Acid on Paraquat-Induced Production of Reactive Oxygen Species and TNF-α in Macrophages.

Authors:  Jiaoyang Li; Xizi Wu; Yao Chen; Renqing Zeng; Yangzi Zhao; Panpan Chang; Danna Wang; Qianwen Zhao; Yunlei Deng; Yongqing Li; Hasan B Alam; Wei Chong
Journal:  Inflammation       Date:  2016-12       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.